Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 8/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6311856 | 0.94 | CETP (0.47) | CETPKCNH2HTR2ASLC6A4NR1H2 | |
| SCHEMBL7082558 | 0.94 | CETP (0.47) | CETPKCNH2HTR2ASLC6A4NR1H2 | |
| SCHEMBL6311861 | 0.88 | CETP (0.45) | CETPKCNH2HTR2ASLC6A4TLR7 | |
| SCHEMBL6312922 | 0.88 | CETP (0.46) | CETPKCNH2HTR2ASLC6A4NR1H2 | |
| SCHEMBL6305337 | 0.85 | CETP (0.67) | CETPKCNH2HTR2ASLC6A4NR1H2 | |
| SCHEMBL6313580 | 0.84 | CETP (0.50) | CETP | |
| SCHEMBL6311199 | 0.83 | CETP (0.58) | CETPKCNH2HTR2ASLC6A4 | |
| SCHEMBL6304914 | 0.83 | CETP (0.47) | CETPHTR2ASLC6A4NR1H2NR1H3 | |
| SCHEMBL6311992 | 0.83 | CETP (0.46) | CETPNR1H2NR1H3 | |
| SCHEMBL6306163 | 0.82 | CETP (0.51) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-12-04 | — | — | US | claimed |
| US-6482862-B1 | Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2002-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225088-A1 | Substituted aromatic policyclic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, PCTP, MTTP | CETP 1/4885KCNH2 2594/4885HTR2A 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.